A Phase 3 interventional study of Ibrutinib and Bendamustine hydrochloride in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 160 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 7 that started in 2012, is one of 14 in phase 3, and was the 9th registered.
2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 578 is above the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson: 3 open now, 7 under way, 2 of them phase 3. Of 16 finished, 3 (19%) have results posted.
Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 3, and was the 2nd registered.
Johnson & Johnson’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1990.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Johnson & Johnson’s 26 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This is a randomized (patients will be assigned by chance to study treatments), double-blind (patients and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL following at least 1 line of prior systemic therapy. Approximately 580 patients will be randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib 420 mg).
Study medication will be administered orally once daily on a continuous schedule. All patients will receive BR as the background therapy plus either ibrutinib or placebo for a maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until disease progression or unacceptable toxicity.
A treatment cycle will be defined as 28 days. The study will include a screening phase, a treatment phase, and a follow-up phase. Study end is defined as when either 80% of the patients have died or 5 years after the last patient is randomized into the study, whichever occurs first.
Patients in treatment arm A (placebo) who complete the treatment phase, with disease progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in treatment arm B), at the investigators discretion. This open-label, next-line treatment with ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from study, or until the study end, whichever occurs earlier. One interim analysis is planned for the study. Efficacy evaluations will include computed tomography scans, laboratory testing, focused physical examinations, bone marrow biopsy and aspirate, and assessment of patient-reported outcomes. In both treatment arms, samples for the development of a population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be collected. Safety will be assessed throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
Drug: Ibrutinib · Drug: Bendamustine hydrochloride · Drug: Rituximab
Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
Drug: Bendamustine hydrochloride · Drug: Rituximab · Drug: Placebo
Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
Form=capsule, route=oral use. Capsule is taken once daily continuously.
Progression-free Survival (PFS)
PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); \>=50% increase in existing lymph nodes; \>=50% increase in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) or \>=50% increase from nadir count confirmed on \>=2 serial assessments if absolute lymphocyte count (ALC) \>=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to CLL; and transformation to a more aggressive histology.
Time frame: Up to 5 years
Overall Response Rate (ORR)
ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum products of up to 6 lymph nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.
Time frame: Up to 5 years
Overall Survival (OS)
OS was defined as the interval between the date of randomization and the date of death from any cause.
Time frame: Up to 5 years
Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response
MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia \[CLL\] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.
Time frame: Up to 5 years
Percentage of Participants With Sustained Hematologic Improvement
Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.
Time frame: Up to 5 years
Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale
Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).
Time frame: Up to 2 years
Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms
The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.
Time frame: From the date of randomization to disease progression (Up to 2 years)
Number of Participants Who Received Subsequent Antineoplastic Therapy
Number of participants who received subsequent antineoplastic therapy was reported.
Time frame: Up to 5 years
Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)
Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.
Time frame: Baseline to EOT (Up to 2 years)
Change From Baseline in FACIT-Fatigue Scale at End of Treatment
FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).
Time frame: Baseline to EOT (up to 2 years)
Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment
EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from "1 = very poor" to "7 = excellent". Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.
Time frame: Baseline to EOT (up to 2 years)
Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment
The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).
Time frame: Baseline to EOT (up to 2 years)
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment
The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline to EOT (up to 2 years)
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.
Time frame: Baseline to EOT (up to 2 years)
| Milestone | Ibrutinib+BR | Placebo+BR | Crossover to Ibrutinib |
|---|---|---|---|
| Started | 289 | 289 | 0 |
| Treated | 287 | 287 | 0 |
| Completed | 259 | 260 | 0 |
| Not completed | 30 | 29 | 0 |
| Withdrew: Lost to follow-up | 8 | 3 | 0 |
| Withdrew: Withdrawal by subject | 22 | 26 | 0 |
| Milestone | Ibrutinib+BR | Placebo+BR | Crossover to Ibrutinib |
|---|---|---|---|
| Started | 0 | 0 | 183 |
| Treated | 0 | 0 | 183 |
| Completed | 0 | 0 | 178 |
| Not completed | 0 | 0 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); \>=50% increase in existing lymph nodes; \>=50% increase in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) or \>=50% increase from nadir count confirmed on \>=2 serial assessments if absolute lymphocyte count (ALC) \>=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to CLL; and transformation to a more aggressive histology.
| Months | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Progression-free Survival (PFS) | 65.12 (55.43 to NA) | 14.32 (13.86 to 16.62) |
ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum products of up to 6 lymph nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.
| Percentage of participants | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Overall Response Rate (ORR) | 87.2 | 66.1 |
OS was defined as the interval between the date of randomization and the date of death from any cause.
| Months | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Overall Survival (OS) | NA (70.93 to NA) | NA (NA to NA) |
MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia \[CLL\] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.
| Percentage of participants | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response | 28.7 | 5.9 |
Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.
| Percentage of Participants | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Hemoglobin | 36.7 | 29.1 |
| Platelets | 30.8 | 21.8 |
Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).
| Months | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale | 6.5 (4.7 to 10.7) | 4.6 (2.8 to 6.4) |
The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.
| Participants | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms | 0 | 0 |
Number of participants who received subsequent antineoplastic therapy was reported.
| Participants | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Number of Participants Who Received Subsequent Antineoplastic Therapy | 52 | 61 |
Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.
| milligram per liter (mg/L) | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT) | -0.46 ± 1.77 | -0.23 ± 2.08 |
FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).
| Units on a scale | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Change From Baseline in FACIT-Fatigue Scale at End of Treatment | -0.9 ± 11.22 | 0.0 ± 11.01 |
EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from "1 = very poor" to "7 = excellent". Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.
| Units on a scale | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment | -2.1 ± 16.34 | -4.1 ± 22.52 |
The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).
| Units on the scale | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Lost weight | 0.1 ± 0.86 | 0.0 ± 0.74 |
| Dry mouth | 0.3 ± 0.96 | 0.1 ± 0.85 |
| Bruises | 0.1 ± 0.61 | 0.0 ± 0.65 |
| Abdominal discomfort | 0.1 ± 0.81 | 0.0 ± 0.76 |
| Temperature going up and down | 0.1 ± 0.93 | 0.0 ± 0.72 |
| Night sweats | -0.6 ± 0.92 | -0.3 ± 1.07 |
| Skin problems | 0.4 ± 1.14 | 0.3 ± 0.96 |
| Feel ill | 0.1 ± 1.08 | 0.2 ± 0.98 |
| Feel lethargic | 0.1 ± 1.01 | 0.0 ± 0.91 |
| Felt slowed down | 0.3 ± 0.80 | 0.0 ± 0.97 |
| Limited in planning activities | 0.2 ± 0.97 | 0.1 ± 0.90 |
| Worried about health in the future | 0.0 ± 0.94 | 0.0 ± 0.97 |
| Trouble with chest infections | 0.2 ± 1.05 | 0.0 ± 0.82 |
| Trouble with other infections | 0.7 ± 1.07 | 0.1 ± 0.86 |
| Repeated courses of antibiotics | 0.9 ± 1.22 | 0.0 ± 0.97 |
| Worried about picking up infection | 0.3 ± 0.96 | 0.2 ± 1.00 |
The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).
| Units on a scale | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment | -4.3 ± 19.58 | 4.0 ± 18.21 |
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.
| Units on a scale | Ibrutinib+BR | Placebo+BR |
|---|---|---|
| Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment | 0.0 ± 0.28 | 0.0 ± 0.24 |
Collected over From the time a signed and dated informed consent form is obtained until 30 days following the last dose of study treatment or until the start of a subsequent systemic antineoplastic therapy, if earlier (up to 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib+BR | 74/287 (25.8%) | 198/287 (69%) | 268/287 (93.4%) |
| Placebo+BR | 107/287 (37.3%) | 127/287 (44.3%) | 271/287 (94.4%) |
| Crossover to Ibrutinib | 57/183 (31.1%) | 105/183 (57.4%) | 157/183 (85.8%) |
| Event | Ibrutinib+BR | Placebo+BR | Crossover to Ibrutinib |
|---|---|---|---|
| PneumoniaInfections and infestations | 48/287 | 26/287 | 34/183 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 30/287 | 22/287 | 2/183 |
| Atrial FibrillationCardiac disorders | 16/287 | 2/287 | 6/183 |
| PyrexiaGeneral disorders | 11/287 | 7/287 | 4/183 |
| BronchitisInfections and infestations | 8/287 | 5/287 | 1/183 |
| SepsisInfections and infestations | 8/287 | 4/287 | 4/183 |
| Respiratory Tract InfectionInfections and infestations | 5/287 | 2/287 | 5/183 |
| Septic ShockInfections and infestations | 6/287 | 2/287 | 5/183 |
| AnaemiaBlood and lymphatic system disorders | 3/287 | 7/287 | 2/183 |
| NeutropeniaBlood and lymphatic system disorders | 7/287 | 6/287 | 0/183 |
| Event | Ibrutinib+BR | Placebo+BR | Crossover to Ibrutinib |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 170/287 | 159/287 | 40/183 |
| DiarrhoeaGastrointestinal disorders | 115/287 | 68/287 | 47/183 |
| NauseaGastrointestinal disorders | 108/287 | 101/287 | 16/183 |
| ThrombocytopeniaBlood and lymphatic system disorders | 90/287 | 69/287 | 24/183 |
| AnaemiaBlood and lymphatic system disorders | 73/287 | 79/287 | 33/183 |
| CoughRespiratory, thoracic and mediastinal disorders | 74/287 | 75/287 | 27/183 |
| PyrexiaGeneral disorders | 74/287 | 60/287 | 22/183 |
| FatigueGeneral disorders | 69/287 | 66/287 | 32/183 |
| Upper Respiratory Tract InfectionInfections and infestations | 69/287 | 50/287 | 36/183 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 45/287 | 64/287 | 1/183 |
| Age, Continuous(years) | Ibrutinib+BR | Placebo+BR | Total |
|---|---|---|---|
| Mean | 63.7 ± 9.82 | 63.3 ± 9.3 | 63.5 ± 9.56 |
| Sex: Female, Male(Participants) | Ibrutinib+BR | Placebo+BR | Total |
|---|---|---|---|
| Female | 96 | 100 | 196 |
| Male | 193 | 189 | 382 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib+BR | Placebo+BR | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 21 | 34 |
| Not Hispanic or Latino | 256 | 253 | 509 |
| Unknown or Not Reported | 20 | 15 | 35 |
| Race/Ethnicity, Customized(Participants) | Ibrutinib+BR | Placebo+BR | Total |
|---|---|---|---|
| White | 264 | 264 | 528 |
| Black | 8 | 6 | 14 |
| Asian | 1 | 2 | 3 |
| American Indian or Alaska Native | 1 | 1 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Other | 3 | 7 | 10 |
| Unknown or not reported | 12 | 9 | 21 |
| Region of Enrollment(Participants) | Ibrutinib+BR | Placebo+BR | Total |
|---|---|---|---|
| ARGENTINA | 3 | 3 | 6 |
| BELGIUM | 14 | 14 | 28 |
| BRAZIL | 10 | 12 | 22 |
| CANADA | 27 | 35 | 62 |
| COLOMBIA | 0 | 1 | 1 |
| CZECH REPUBLIC | 12 | 11 | 23 |
| FRANCE | 16 | 11 | 27 |
| GERMANY | 10 | 11 | 21 |
| GREECE | 12 | 5 | 17 |
| ISRAEL | 14 | 12 | 26 |
| MEXICO | 1 | 2 | 3 |
| POLAND | 19 | 20 | 39 |
| PORTUGAL | 7 | 12 | 19 |
| RUSSIAN FEDERATION | 50 | 50 | 100 |
| SOUTH KOREA | 0 | 1 | 1 |
| SPAIN | 9 | 9 | 18 |
| SWEDEN | 2 | 4 | 6 |
| TURKEY | 24 | 27 | 51 |
| UKRAINE | 16 | 14 | 30 |
| UNITED KINGDOM | 5 | 9 | 14 |
| UNITED STATES | 38 | 26 | 64 |
Showing the first 100 of 160 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2012 to primary completion in Jan 2019, 76 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 76 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →
Janssen Research & Development, LLC →